Trial Profile
Mirvaso® Utilisation and Patient Satisfaction Evaluation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2021
Price :
$35
*
At a glance
- Drugs Brimonidine (Primary)
- Indications Erythema
- Focus Therapeutic Use
- Acronyms MUSE
- Sponsors Galderma; Galderma Research & Development
- 18 Feb 2022 Route and form of the drug is assumed from RDI.
- 17 May 2016 Status changed from recruiting to completed.
- 11 Nov 2015 New trial record